Abstract

IntroductionWe aimed to investigate whether 18F-FDG PET metabolic heterogeneity reflects the heterogeneity of estrogen receptor (ER) and progesterone receptor (PR) expressions within luminal non-metastatic breast tumors and if it could help in identifying patients with worst event-free survival (EFS).Materials and methodsOn 38 PET high-resolution breast bed positions, a single physician drew volumes of interest encompassing the breast tumors to extract SUVmax, histogram parameters and textural features. High-resolution immunochemistry (IHC) scans were analyzed to extract Haralick parameters and descriptors of the distribution shape. Correlation between IHC and PET parameters were explored using Spearman tests. Variables of interest to predict the EFS status at 8 years (EFS-8y) were sought by means of a random forest classification. EFS-8y analyses were then performed using univariable Kaplan-Meier analyses and Cox regression analysis. When appropriate, Mann-Whitney tests and Spearman correlations were used to explore the relationship between clinical data and tumoral PET heterogeneity variables.ResultsFor ER expression, correlations were mainly observed with 18F-FDG histogram parameters, whereas for PR expression correlations were mainly observed with gray-level co-occurrence matrix (GLCM) parameters. The strongest correlations were observed between skewness_ER and uniformity_HISTO (ρ = −0.386, p = 0.017) and correlation_PR and entropy_GLCM (ρ = 0.540, p = 0.001), respectively. The median follow-up was 6.5 years and the 8y-EFS was 71.0%. Random forest classification found age, clinical stage, SUVmax, skewness_ER, kurtosis_ER, entropy_HISTO, and uniformity_HISTO to be variables of importance to predict the 8y-EFS. Univariable Kaplan-Meier survival analyses showed that skewness_ER was a predictor of 8y-EFS (66.7 ± 27.2 versus 19.1 ± 15.2, p = 0.018 with a cut-off value set to 0.163) whereas other IHC and PET parameters were not. On multivariable analysis including age, clinical stage and skewness_ER, none of the parameters were independent predictors. Indeed, skewness_ER was significantly higher in youngest patients (ρ = −0.351, p = 0.031) and in clinical stage III tumors (p = 0.023).ConclusionA heterogeneous distribution of ER within the tumor in IHC appeared as an EFS-8y prognosticator in luminal non-metastatic breast cancers. Interestingly, it appeared to be correlated with PET histogram parameters which could therefore become potential non-invasive prognosticator tools, provided these results are confirmed by further larger and prospective studies.

Highlights

  • We aimed to investigate whether 18F-FDG Positron Emission Tomography (PET) metabolic heterogeneity reflects the heterogeneity of estrogen receptor (ER) and progesterone receptor (PR) expressions within luminal non-metastatic breast tumors and if it could help in identifying patients with worst event-free survival (EFS)

  • The causes of exclusion were as follows: PET-Computed Tomography (CT) not performed prior to surgery (n = 8), metastatic tumors on initial staging (n = 4), missing data (n = 1), breast lesions not 18F-FDG avid (n = 3), hormonal receptors (ER and PR) negative tumors (n = 7), IHC slide unusable (n = 1), and volume of interest too small to be analyzed with LifeX software (n = 1)

  • We decided to focus on EFS and it appeared that immunochemistry histogram parameters of estrogen receptors, and especially skewness, are predictors of 8y-EFS together with age and clinical stage, whereas none of the progesterone receptors were

Read more

Summary

Introduction

We aimed to investigate whether 18F-FDG PET metabolic heterogeneity reflects the heterogeneity of estrogen receptor (ER) and progesterone receptor (PR) expressions within luminal non-metastatic breast tumors and if it could help in identifying patients with worst event-free survival (EFS). An attempt to replicate molecular classification using conventional IHC characteristics of the tumor, including ER, PR, HER-2, and Ki67 showed low concordance with gene expressions profile [4, 5]. When it comes to breast cancer staging, 2-deoxy-2[18F]-fluoro-D-glucose (18F-FDG) PET/CT is a well-established examination for the initial staging of locally advanced breast cancer [6,7,8,9], as it displays excellent capabilities for extra-axillary nodal and distance metastases detection. With the newly growing development of metabolic heterogeneity features in nuclear medicine, the PET community is regaining interest in the value of 18F-FDG PET/CT for the non-invasive biological

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.